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Available online 28 January 2011Marijuana (Cannabis sativa) is one of the most widely used illicit drugs in the world. Its use is
associated with impairments in cognitive function. We previously reported that Δ9-
tetrahydrocannabinol (Δ9-THC), the primary psychoactive component of marijuana,
impaired spatial working memory in the radial maze task when injected intracortically
(IC) into themedial prefrontal cortex (mPFC) of rats. Here, we used this paradigm to evaluate
the involvement of prefrontal dopamine receptors in working memory disruption induced
by Δ9-THC. Intracortical pre-treatment of animals with either the D1- or D2-like dopamine
receptor antagonists SCH 23390 or clozapine, respectively, significantly reduced the number
of errors rats made in the radial maze following treatment with Δ9-THC also administered
intracortically. These results were obtained in the absence of locomotor impairment, as
evidenced by the time spent in each arm a rat visited. Our findings suggest that prefrontal
dopamine receptors are involved in Δ9-THC-induced disruption of spatial working memory.
This interaction between the cannabinoid system and dopamine release in the PFC
contributes to new directions in research and to treatments for cognitive dysfunctions
associated with drug abuse and dependence.







The prefrontal cortex (PFC) is a set of neocortical areas
involved in a variety of cognitive functions that are instru-
mental in working memory (WM) processing (Baddeley, 1992;
D'Esposito et al, 2000; de Saint Blanquat et al, 2010). Damage to
the PFC of rodents, nonhuman primates, and humans
produces profound deficits in performance on WM tasks
(Passingham, 1985; Funahashi et al, 1993; Miller, 2000;
Tsuchida and Fellows, 2009). Working memory has been
described as a multi-component system (Baddeley, 2003;raduação em Ciências F
9042-755 Vitória, ES, Braz
M. Rodrigues).
 the Elsevier OA license.Repovs and Baddeley, 2006) or a collection of distinct cognitive
processes (Floresco and Phillips, 2001; Bunting and Cowan,
2005; Cowan, 2008) that provides active maintenance of trial-
unique information in temporary storage. In both laboratory
tasks and in normal cognition, WM enables manipulation,
processing, and retrieval of memories, which are converted
efficiently into long-term memory after both short (seconds)
and long (minutes to hours) delays (Fuster, 1997; Floresco and
Phillips, 2001; Phillips et al, 2004; Funahashi, 2006; Rios
Valentim et al, 2009). During the delay period of WM tasks,
brain imaging studies in humans using positron emissionisiológicas, Centro de Ciências da Saúde, Universidade Federal do
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Fig. 1 – Location of intracerebral infusion sites. A bilateral
cannulawas implanted in subareas of themPFC. Black circles
depict the intracerebral infusion sites of Δ9-THC, and gray
circles depict the sites of DA antagonist treatment.
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(fMRI) have shown increased blood flow within the PFC
(Jonides et al., 1993; Petrides et al, 1993; Badre and D'Esposito,
2007). Consistent with the increased perfusion, imaging
studies have also shown higher activity of the PFC during
the delay period ofWM tasks (Wagner et al, 2001; Rypma, 2006;
Motes and Rypma, 2010). Thus, PFC neurons or networks seem
to be equipped with a mechanism that enables them to hold
active neural representations of goal-related information and
to protect those representations from interfering stimuli
during the delay period.
In previous studies, we demonstrated the disruptive effects
on spatial working memory of themajor psychoactive compo-
nent of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), following
both systemic administration and local injection into the
medial PFC (mPFC) (Nakamura et al, 1991; Silva de Melo et al,
2005). The impairing effects of CB1 receptor ligand Δ9-THC, the
endogenous CB1 receptor agonist anandamide and synthetic
cannabinoids on learning and on performance of diverse
memory tasks in rodents (Fehr et al, 1976; Stiglick and Kalant,
1983; Nakamura et al, 1991; Brodkin andMoerschbaecher, 1997;
Wise et al, 2009; Robinson et al, 2010) and nonhuman primates
(Zimmerberg et al, 1971; Galbicka et al, 1980; Winsauer et al,
1999; Nakamura-Palacios et al, 2000) are well documented
(Lichtman et al, 2002), but efforts are needed to better
understand the mechanisms underlying that impairment.
It has long been appreciated that dopamine (DA) has a
powerful influence on the cognitive functions of the PFC,
including WM (Brozoski et al., 1979; Sawaguchi and Goldman-
Rakic, 1991; Goldman-Rakic, 1996; Zahrt et al, 1997; Lidow et al,
2003; Robbins and Arnsten, 2009). Additionally, interactions
between DA release and cannabinoids have been reported in
several brain areas in vitro and in vivo (Gardner and Lowinson,
1991; Fernández-Ruiz et al, 2010). These interactions consist in
enhancement of DA release induced by cannabinoids (Poddar
and Dewey, 1980; Jentsch et al., 1998; Bossong et al., 2009), no
effect of cannabinoids over dopaminergic neurons (Szabo
et al., 1999), and inhibition of DA release (Cadogan et al.,
1997). Probably these different data are due to the
variability in brain area and applied methodology, but it
shows how this theme needs to be more defined.
To explore further the mechanisms by which Δ9-THC
impairs WM, as previously reported by our laboratory, this
study sought to determine if DA activation in the mPFC is
directly involved in this disruption of WM induced by Δ9-THC.
The dopamine antagonists SCH 23390 (SCH) and clozapine
(CZP) were used to investigate the involvement of D1-like and
D2-like dopamine receptors, respectively, on Δ9-THC action in
the mPFC.2. Results
All data presented in this study were from animals whose
cannulae were successfully implanted in the mPFC. Fig. 1
shows the proper location of the bilateral cannula. Most often,
the cannulae were placed in the Cg1 and Cg3 areas from the
anterior cingulate and prelimbic cortex, subareas of themPFC,
especially in the 3.7-, 3.2-, and 2.7-mm sections depicted in
diagrams from Paxinos and Watson (1986). Moreover, allanimals progressively improved in task performance in the
radial maze. After 2 months of training, all animals achieved
the baseline criterion of no more than one error in each of at
least three consecutive sessions.
Pre-delay task is the first step of the experiment, and as
expected, animals that were trained in the radial maze until
reach the criteria for experiment did not present any
statistical difference in the mean of errors soon after (5 min)
drugs administration. Accordingly, there is no effect on what
we call reference (procedural) memory measured in the
radial maze soon after Δ9-THC and antagonist treatment
(data not shown).
2.1. Effect of the D1-like dopamine receptor antagonist
SCH 23390
In the 1-h post-delay period, statistically significant difference
was found among the combination of SALwith different doses
of Δ9-THC [F(1, 16)=11.34; p=0.0039, ANOVA]. Animals treated
with SAL followed by 100 μg Δ9-THC increased (p<0.05 by
Dunn's test) themean number of errors in the radialmaze task
when compared to SAL followed by VEH. We assert that this
result was obtained in the absence of locomotor impairment
because when choice latency (i.e., the time that animals spent
Fig. 2 – SCH 23390 administered prior to Δ9-THC prevents
spatial working memory impairment in the eight-arm radial
maze task after a 1-h delay. Values are mean±SEM; *p<0.05
compared to VEH after SAL administration and ++p<0.01
compared to Δ9-THC (32, 100, or 180 μg) after SAL. Data
(n=9 rats) were analyzed using two-wayANOVAwithDunn's
(Bonferroni) post-hoc test.
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difference among all combinations (Table 1).
To test if D1-like DA receptors contributed to the increase in
errors made by Δ9-THC-treated rats, we pre-treated rats with
the antagonist SCH (1 μg IC). No difference was observed
between SCH and SAL pre-treatments before VEH, suggesting
SCH had no effect on baseline WM (Fig. 2, first two bars).
Nevertheless, there was a significant interaction in the
analysis of SCH administration prior to different doses of Δ9-
THC [F(3, 48)=7.11; p=0.0005, ANOVA]. Animals treated with
SCH followed by doses of 100 and 180 μg Δ9-THC significantly
(p<0.01, by Dunn's test) reduced the mean number of errors in
the radial maze, thus preventing the impairing effect of Δ9-
THC onWM. These results support the involvement of D1-like
dopamine receptors in the disruptive effect onWM induced by
Δ9-THC in the mPFC (Fig. 2).
2.2. Effect of the D2-like dopamine receptor
antagonist clozapine
In the 1-h post-delay period, statistically significant difference
was found among the combination of HCl with different doses
of Δ9-THC [F(1, 18)=16.02; p=0.0008, ANOVA]. Animals treated
with Δ9-THC at doses of 32 μg (p<0.01, by Dunn's test) and 100
(p<0.01, by Dunn's test) administered after 0.05 N HCl elicited
more errors in radial maze performance compared to 0.05 N
HCl followed by VEH. The time spent in each arm was also
measured, and there was no significant difference among any
of the combinations (Table 2), suggesting that the decrease in
performance was not associated with locomotor activity
impairment. To test if D2-like dopamine receptors participate
in the disruptive effect produced by Δ9-THC, the antagonist
CZP was administered at a dose of 3.2 μg IC prior to both VEH
and all doses of Δ9-THC. Compared to 0.05 N HCl (VEH
treatment), CZP had no effect on baseline performance
(Fig. 3, first two bars). However, there was a significant
interaction in the analysis of CZP administration prior to
different doses of Δ9-THC [F(3, 54)=8.09; p=0.0002, ANOVA].
Animals treated with CZP followed by 32 (p<0.01, by Dunn's
test) and 100 (p<0.01, by Dunn's test) μg Δ9-THC significantly
prevented the impairing effect of Δ9-THC on spatial workingTable 1 – Locomotor activity in the SCH experiment (n=9
rats). Time in seconds (mean±SEM) spent by animals in
each arm in the eight-arm radial maze task. There was no
significant difference among the different treatment
combinations. Data were analyzed using two-way
ANOVA with Bonferroni post-hoc test.
Drug combinations
in SCH experiment
Mean time spent±SEM (s)
Pre-delay Post-delay
SAL/VEH 14.11±2.64 14.11±0.78
SAL/Δ9-THC 32 14.00±0.70 12.33±0.81
SAL/Δ9-THC 100 11.88±1.00 12.66±1.32
SAL/Δ9-THC 180 12.22±1.76 11.22±1.21
SCH/VEH 15.44±2.35 12.88±1.05
SCH/Δ9-THC 32 11.55±0.72 12.77±0.87
SCH/Δ9-THC 100 15.88±3.52 13.88±1.22
SCH/Δ9-THC 180 13.11±1.04 12.00±0.98memory. These results support the involvement of D2-like
dopamine receptors in the disruptive effect on working
memory induced by Δ9-THC in the mPFC (Fig. 3).3. Discussion
The prefrontal cortex serves a variety of functions, including
WM. Our experiments demonstrate that the impairment of
spatialWM induced by intracortical injection of the exogenous
cannabinoid Δ9-THC is prevented by the dopamine receptor
antagonists SCH and CZP. Additionally, the present results
also provide evidence that the cannabinoid induces disruption
in spatial workingmemory. It was observed a different pattern
in the three doses of Δ9-THC in the experiments with D1 or D2
antagonists. Besides the fact that the experiments are
independent (different animals), the vehicle solution for the
drugs was different, being SAL for SCH and HCl for CZP. ThisTable 2 – Locomotor activity in the CZP experiment (n=10
rats). Time in seconds (±SEM) spent by animals in each
arm in the eight-arm radial maze task. There was no
significant difference among the different treatment
combinations. Data were analyzed using two-way
ANOVA with Bonferroni post-hoc test.
Drug combinations
in CZP experiment
Mean time spent±SEM (s)
Pre-delay Post-delay
HCl/VEH 14.70±1.89 13.90±1.57
HCl/Δ9-THC 32 12.20±0.80 10.90±0.50
HCl/Δ9-THC 100 13.10±0.72 12.50±0.37
HCl /Δ9-THC 180 13.30±1.47 14.20±1.50
CZP/VEH 13.40±1.09 12.70±1.07
CZP/Δ9-THC 32 11.90±0.64 11.00±0.51
CZP/Δ9-THC 100 11.50±0.68 11.10±0.54
CZP/Δ9-THC 180 12.70±0.76 11.80±0.64
Fig. 3 – Clozapine administered prior to Δ9-THC (32 and
100 μg) prevents spatial working memory impairment in the
eight-arm radial maze task after a 1-h delay. Values are
mean±SEM; **p<0.01 compared to VEH after HCl
administration. ++p<0.01 compared to Δ9-THC after HCl. Data
(n=10 rats) were analyzed using two-way ANOVA with
Dunn's (Bonferroni) post-hoc test.
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THC treatment or its VEH between SCH and CZP experiments.
Administration of Δ9-THC significantly increased the
number of errors in the radial maze task, and this finding is
in accordance with published reports of Δ9-THC-induced
spatial learning deficits in rats (Nakamura et al, 1991; Lichtman
et al, 1995; LichtmanandMartin, 1996; Silva deMelo et al, 2005).
Memory impairment induced by Δ9-THC is mediated directly
through CB1 cannabinoid receptors (Mallet and Beninger, 1998;
Varvel et al, 2001; Varvel and Lichtman, 2002). As there is a high
density of these cannabinoid receptors in the PFC (Wedzony
and Chocyk, 2009; Eggan et al, 2010; Mato et al, 2010), they
probably mediate the Δ9-THC-induced impairment of WM in
this brain area.
Briefly, the synaptic function of cannabinoids is more
compatible with a modulatory role than as a classic transmit-
ter. The frequent, although not exclusive, presynaptic location
of CB1 receptors allows cannabinoids to directly influence
presynaptic events, such as the synthesis and release of
specific neurotransmitters, especially γ-aminobutyric acid
(GABA) and glutamate. Indeed, CB1 receptors are frequently
located on neurons containing these neurotransmitters
(Lafourcade et al, 2007; Chiu et al, 2010). The combination of
numerous pharmacological, electrophysiological, and immu-
nohistochemical studies suggest that cannabinoid receptors
function as retrograde signals at the synapse, directly
preventing an excess of excitation or inhibition in glutama-
tergic or GABAergic neurons, respectively (Schlicker and Kath-
mann, 2001; Piomelli, 2003; Kano et al, 2009).
DA has been frequently linked to the action of cannabi-
noids within the CNS. Nevertheless, it is generally accepted
that DA transmission is not the first target for the action of
cannabinoid agonists; rather, the DA effects would be most
likely indirect (Fattore et al, 2008; Lupica et al, 2004). These
effects involve a variety of regulatory functions exerted by
mesocorticolimbic dopaminergic neurons, such as the controlof cognitive processes, learning, and memory. Considering
these data and our previous results, in whichwe observed that
activation of the CB1 cannabinoid receptor in the PFC
culminated in disruption of spatial WM (Silva de Melo et al,
2005), we have questioned the involvement of DA receptors in
this response. In the present study, DA antagonists were
directly injected into the mPFC in order to assert that output
DA neurons of this area would be tested. Accordingly, we
found that pre-treatment with both D1-like and D2-like DA
antagonists prevented the spatial WM impairment induced by
Δ9-THC in rats, suggesting that the impairment is due to
excess dopaminergic activation in the mPFC.
Since the blockade of DA receptors directly in the mPFC
prevented the disruptive effect induced by Δ9-THC, we
hypothesized in the present study that this disruption is the
resultant of an excess of dopaminergic activation in themPFC.
This study provides the first evidence of dopaminergic
involvement in the disruption of spatial WM after Δ9-THC
administration into the PFC. DA release occurs in several areas
of brain reward circuits after administration of Δ9-THC (Lupica
et al, 2004), as does an enhancement ofmesolimbic DA neuron
firing (Gessa et al, 1998). However, as cited above, these effects
of Δ9-THC over DA release are most likely indirect.
The connection between DA receptor stimulation and
cognitive functions has been examined systematically. An
elegant study designed by Phillips et al. (2004) showed that DA
efflux is elevated in themPFC of rats after an extended delay of
30 min in a situation in which spatial memory for the correct
location of food had to be recalled. The increase in DA efflux in
themPFCwas not related to reward but to the accuracy ofWM,
confirming the correlation of this function with DA activation.
Furthermore, several other studies performedwith high DA
levels support the finding that excess DA release and turnover
in the PFC are associated with impairment of spatial WM
(Murphy et al, 1996; Zahrt et al, 1997; Seamans and Yang, 2004;
Phillips et al, 2004). Dopaminergic regulation of frontal cortical
cognition was studied by Jentsch et al. (1998), who observed
that high doses of Δ9-THC (20 mg/kg/day for 14 days) that
seemed nontoxic to mesocortical DA neurons selectively
reduced PFC DA metabolism in rats.
Although the involvement of D1-like receptors in WM is
widely recognized, recent studies have demonstrated the
involvement of D1- and D2-like DA receptors on WM or
executive functions in the PFC, and it has been suggested
that when DA levels are high, the prefrontal network is
modulated not only by D1 but mainly by D2 receptors (Floresco
et al, 2006). Glickstein et al. (2002) observed that mice lacking
D2 receptors show WM deficits (2002). Additionally, systemic
administration of D2 agonists in humans improved cognitive
functions, including WM and executive functions (McDowell
et al, 1998), whereas administration of D2 antagonists im-
paired such functions (Mehta et al, 1999). These findings
reveal the complexity of this issue, although it is known there
is an optimal level of DA activation for primeWMperformance
(Nieoullon, 2002; Robbins and Arnsten, 2009).
Clozapine has antagonistic effects at a variety of transmit-
ter receptors important for memory function, including
muscarinic acetylcholinergic, serotonergic and dopaminergic
receptors. Like many of the typical antipsychotic medications,
clozapine acts as an antagonist at the D2 and D4 dopaminergic
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alone, has been described to impair spatial working memory
and it may be associated with anticholinergic properties of
clozapine rather than its action on dopamine receptors
(Goldberg et al., 1993; Addy and Levin 2002; Addy et al, 2005).
In the present study, clozapine alone did not exhibit any effect
in spatial working memory since the dose administered here
was chosen after dose–effect curve performed exactly to
exclude any possibility of drug alone effect.
SCH has beenwidely described as a selective dopamine D1-
like receptor antagonist and this is not commonly described as
having effect alone over cognitive function as working
memory. So, we administered SCH or CZP with no effect
alone before dopaminergic activation by Δ9-THC and, their
antagonism in D1 or D2-like DA receptor do explain the
improvement in cognitive function.
Certainly, the interactions between DA, cannabinoids, and
WMare complex. In addition to the fact that cannabinoids can
alter DA transmission and DA-related behaviors via an
indirect action on GABAergic (and glutamatergic) neurons,
studies have found that cannabinoids can also activate
noncannabinoid receptors, such as transient receptor poten-
tial vanilloid 1 (TRPV1), on dopaminergic neurons (Fernández-
Ruiz et al., 2010). The role of this channel in the central
nervous system is widely described though poorly defined.
Anandamide, AM404 orN-arachidonoyl-dopamine (NADA) are
able to bind to TRPV1 (Fernández-Ruiz et al., 2010) and it is
known that anandamide can exert its actions through TRPV1
cannabinoid receptor aswell as CB1 (Starowicz et al., 2007) and
this implies a possible cross-talk between the endovanilloid
and endocannabinoid systems under either physiological or
pathological conditions. We suggest that Δ9-THC administra-
tion, that is a CB1 ligand, may dislocate anandamide from CB1
receptor to TRPV1. This interaction deserves to be reminded in
discussions about intriguing results as observed in several
studies about drug abuse and neuropsychiatric disorders.
The present study provides evidence of the involvement of
D1-like andD2-like DA receptors in the disruptive effect onWM
of Δ9-THC in the PFC. Further, WM impairment induced by
direct activation of the cannabinoid receptor CB1, but pre-
vented by DA antagonists, might be due to dynamic signaling
involving multiple components, and this interaction remains
to be more defined.4. Experimental procedures
4.1. Subjects
Male Wistar rats (n=19) from our own breeding colony (PPG-
CF, CCS, UFES), weighing 250–300 g, were individually housed
in a temperature-controlled (20–22 °C) room and maintained
on a 12-h light/dark cycle. The rats were food-restricted
throughout the duration of the experiments to keep them at
85% of their free-feeding body weight (adjusted for growth).
The care and use of all subjects in this study were conducted
in agreement with the ethical principles of the Brazilian
College in Animal Experimentation (COBEA, http://www.
cobea.org.br), which in turn conform to international guide-
lines for research involving animals.4.2. Radial arm maze
The apparatus consisted of eight symmetrical arms (70 cm
long and 10 cm wide, with side walls 4 cm high), radiating
from an octagonal central platform (33 cmwide). The platform
was enclosed by a wall 30 cm high that served as a frame for
guillotine doors at the beginning of each arm. These doors
were operated by overhead strings and regulated access to
each arm. As a reward, a piece of a peanut was placed in a
small black cup at the end of each arm. The radial maze was
made of transparent Plexiglasmounted over wood of the same
shape, and it was supported by ametal structure 100 cm above
the floor. The maze was kept in a constant position in the
middle of a square room and illuminated by fluorescent lights.
The door and a large window in the room were occluded by
gray paint, and all of the other objects in the room (e.g.,
cabinet, rack, desk, bench, and chairs) were maintained in the
same position during the experiment.
All procedures in the radial maze were performed as
previously described (Silva de Melo et al., 2005). Briefly, each
session was performed once a day. The animals were
introduced to the apparatus and habituated to the environ-
ment and the manual handling by the experimenter. During
training, the animals remained in the maze until they had
entered each arm of the maze once in a given session, and
training continued until the rats reached a criterion of nomore
than one error (re-entry into an arm previously visited during
the same session) per session over three consecutive sessions
(acquisition of the task). After their performance stabilized in
the radial maze, the animals underwent surgery for implan-
tation of a bilateral cannula in the mPFC.
For the delay procedure, the rats were initially allowed to
enter each of four randomly pre-selected arms to get a reward,
whereas access to the other four arms was blocked (pre-delay
period). After obtaining the reward from each of the pre-
selected arms, the animals were returned to their home cages
for an interval of retention. After the delay period, all of the
maze armswere opened, and the animalswere returned to the
center of the maze and allowed to complete choices to obtain
rewards in the four previously obstructed arms (post-delay
period). So, pre-delay is the reference (procedural) memory
and after this first session performance (pre-delay), the animal
may retain the information about arms already visited
“online” until the performance of the second session (post-
delay) that occurs one hour later (the memory that was
evaluated in this study).
4.3. Cannula implantation
Rats were anesthetized with chloral hydrate (400 mg/kg, i.p.),
and their heads were set in a stereotaxic apparatus (David
Kopft Instruments, USA). A bilateral double cannula (2 mm
long, 26 gauge; Plastics One Inc., VA, USA) was implanted at
the confluence of the Cg1, Cg2, and Cg3 areas of the mPFC,
according to the following parameters relative to bregma:
+2.5 mm AP, ±1 mm L, and −2.0 mm V (Paxinos and Watson,
1986). The double guide cannula was anchored to the skull
with dental acrylic and four small screws and was protected
with a double dummy cannula and a dust cap. Each rat was
given a 5-day recovery period after surgery. Animalswere then
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surgery baseline performance.
4.4. Drugs and administration
An alcohol (100 vol%) stock solution of Δ9-THC (National
Institute on Drug Abuse, Rockville, MD, USA) was stored at
4 °C. For the experimental procedures, the alcohol was
evaporated, and the residue was resuspended in a vehicle
solution (VEH) composed of emulphor (30%) and dimethylsulf-
oxide at final concentrations of 64, 200, and 360 mg/ml. The
volume injected was 0.5 μl, resulting in a final intracortical (IC)
administration of 32, 100, and 180 μg Δ9-THC. Dopaminergic
drugs were purchased from Sigma-Aldrich (MO, USA). The
antagonist SCH 23390 [R(+)-7-chloro-8-hydroxy-3-methyl-1-
phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine hydrochloride]
was diluted in distilled water to 2 mg/ml, and 0.5 μl were
injected, resulting in a final IC administration of 1 μg. The
antagonist CZP [8-chloro-11-(4-methylpiperazin-1-yl)-5 H-
dibenzo[b,e][1,4]diazepine] was diluted in 0.05 N HCl to
6.4 mg/ml, and 0.5 μl were injected, resulting in a final IC
administration of 3.2 μg. These doses of SCH and CZP were
selected because previous studies in our lab had shown that
they have no effect alone on radial maze performance. For
control solutions, VEH alone and either saline (SAL) or HCl
were administered.
To administer drugs IC to the mPFC, the dust cap and
dummy cannula were removed, and a stainless steel, double
internal cannula (33 gauge; Plastics One Inc.) extending to
2.7 mm was lowered through the double guide cannula to the
sites of infusion. A double cannula connector (Plastics One
Inc.) connected the double internal cannula to two 10-μl
Hamilton syringes. A volume of 0.5 μl was delivered to each
side of the mPFC over 90 s through a microprocessor syringe
pump (Series 100; Stoelting, IL, USA). The experimenter gently
handled subjects while the drug was administered. A 90-s
diffusion period was allowed before removal of the internal
cannula and replacement of the dummy cannula and the dust
cap. Using this infusion procedure, animals (n=9) bilaterally
cannulated in the mPFC and well trained in the radial maze
procedure first received an acute IC administration of 1 μg SCH
or SAL, followed 10 min later by an acute IC administration of
32, 100, or 180 μg Δ9-THC or VEH. A separate cohort of animals
(n=10) received an acute IC administration of 3.2 μg CZP or
0.05 NHCl, followed 10 min later by an acute IC administration
of 32, 100, or 180 μg Δ9-THC or VEH.Well-trained ratswere then
tested in the radial maze task after a 5-min interval (pre-delay
task) and after 1 h (post-delay task). So, drugs were injected in
well-trained rats before any testing in the maze on a test day.
The sequence of drug combinations for each animal was
determined by a Latin Square schedule, which ensured that no
animal repeated a given sequence of injections. A period of
7 days with no drug treatment was interposed between drug
administrations, and a training session demonstrating stable
responding was required prior to each drug administration.
4.5. Histology
After all experimental procedures, animals were lightly
anesthetized with chloral hydrate (400 mg/kg, i.p.), and 0.5 μl(the same volume of drug administered) of a 1% methylene
blue solution (Biotec, PR, Brazil) was administered IC. After-
wards, the rats were deeply anesthetized and intracardially
perfused with saline followed by 4% formaldehyde. Brains
were removed andmaintained in 8% formaldehyde for at least
3 days. Then the brains were serially sectioned with a
vibratome into slices of approximately 80 μm (Vibratome
Tissue Section System, 1000 Plus, MO, USA). These slices
were stained with neutral red and if cannula had been
properly placed, a blue dye would be seen in the mPFC (Cg1,
Cg2, Cg3 and Fr2 areas), as identified in diagrams from a rat
brain atlas (Paxinos and Watson, 1986).
4.6. Data analysis
The number of errors and the time spent in each arm in the
pre- or post-delay periods of 1-h delay taskswere expressed as
the means±SEM. Drug interactions (within Δ9-THC doses and
between antagonist effects) were analyzed using two-way
repeated-measures ANOVA followed by Dunn's (Bonferroni)
correction as a post-hoc test for each pair of different groups
being compared. A p-value of 0.05 or less was considered as
indicative of a significant difference. The software GB-Stat
Professional Statistics and either Graphics version 6.5 or
GraphPad Prism 4.0 were employed for statistical analysis
and graphic representation, respectively.Acknowledgments
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